Amid its global push to reach more patients with SGLT2 inhibitor Jardiance, Boehringer Ingelheim reported solid sales growth for the med last year. Now, armed with two new FDA approvals in a span of ...
Besides the diabetes and obesity duo of Mounjaro and Zepbound, the SGLT2 inhibitor Jardiance and the CDK4/6 cancer drug Verzenio were cited as the main growth drivers for Eli Lilly’s first quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results